36 results on '"Pennell, Nancy"'
Search Results
2. Homologous Recombination Can Restore Normal Immunoglobulin Production in a Mutant Hybridoma Cell Line
3. Association of Clinical Status of Follicular Lymphoma Patients after Autologous Stem Cell Transplant and Quantitative Assessment of Lymphoma in Blood and Bone Marrow as Measured by SYBR Green I Polymerase Chain Reaction
4. Clinical Effectiveness of Combination Immunotherapy DPX-Survivac, Low Dose Cyclophosphamide, and Pembrolizumab in Recurrent/Refractory DLBCL: The Spirel Study
5. 356 Baseline PD-L1 expression and tumor immune infiltration is associated with clinical response in patients with r/r DLBCL treated with DPX-Survivac, low-dose cyclophosphamide and pembrolizumab
6. Human lymphoblastoid cell lines expressing mutant p53 exhibit decreased sensitivity to cisplatin-induced cytotoxicity
7. What is remission in follicular lymphoma and what is its relevance?
8. T-cell analysis in identical twins reveals an impaired anti-follicular lymphoma immune response in the patient but not in the healthy twin
9. Combination of DPX-Survivac, Low Dose Cyclophosphamide, and Pembrolizumab in Recurrent/Refractory DLBCL: The Spirel Study
10. Immunotherapy with rituximab following high-dose therapy and autologous stem-cell transplantation for mantle cell lymphoma
11. Management of newly diagnosed high-risk and intermediate-risk follicular lymphoma with90Y ibritumomab tiuxetan in a phase II study
12. Autologous stem cell transplant and combination immunotherapy of rituximab and interferon-α induces prolonged clinical and molecular remissions in patients with follicular lymphoma
13. Risk Adjusted Management of Newly Diagnosed High and Intermediate FLIPI Follicular Lymphoma Using (90)Y Ibritumomab Tiuxetan
14. Autologous stem cell transplant and combination immunotherapy of rituximab and interferon‐α induces prolonged clinical and molecular remissions in patients with follicular lymphoma.
15. Management of newly diagnosed high-risk and intermediate-risk follicular lymphoma with 90 Y ibritumomab tiuxetan in a phase II study.
16. Sustained Immune Competency and Long Term Molecular Remissions in FL Patients with FLIPI Risk Factors >1, Treated Front Line with R-CHOP Followed by Consolidative 90 Y-Radioimmunotherapy and Maintenance Rituximab
17. KIT Gene Mutations and Patterns of Protein Expression in Mucosal and Acral Melanoma
18. First Evidence for High Incidence of Complete and Sustained Molecular Remissions and Maintenance of Immune Responses in Patients Receiving Consolidation with Y90 Ibritumomab Tiuxetan (90Y-RIT) Post R-CHOP for Newly Diagnosed Advanced Stage High and Intermediate Risk Follicular Lymphoma
19. An Index of SNPs in Immune Genes May Enhance the Prognostic Value of IPI in Patients with Aggressive Non-Hodgkin's Lymphoma
20. The Addition of Rituximab and/or Alpha-Interferon to High Dose Chemotherapy and Autologous Stem Cell Transplantation for Patients with Relapsed Follicular Lymphoma Produces Durable Progression Free Survival and Molecular Remissions
21. Hypogammaglobulinemia Following Rituximab and High-Dose Therapy and Autologous Stem-Cell Transplant: Incidence and Predictors of Prolonged Immunoglobulin Deficiencies
22. Prolonged Clinical and Molecular Remissions Following High-Dose Therapy/Autologous Stem Cell Transplantation (HDT/ASCT) and Rituximab and Interferon-alpha Maintenance for Relapsed High-Risk Follicular Lymphoma.
23. Autologous Stem-Cell Transplant with a Rituximab Purge and Maintenance vs. Standard Chemotherapy for Mantle Cell Lymphoma: Extended Follow-Up of a Matched Pair Analysis.
24. Rituximab Increases Response to ESHAP in Relapsed, Refractory, and Transformed Aggressive B-Cell Lymphoma.
25. A Simplified Real-Time PCR Method for the Quantification of Minimal Residual Disease in Follicular Lymphoma.
26. High Dose Therapy / ASCT with Rituximab for In-Vivo Purging and Post-ASCT Consolidation in Relapsed Follicular Lymphoma Achieves Prolonged Clinical and Molecular Remissions.
27. Prolonged Molecular and Clinical Remission after Treatment of a Patient with Follicular Lymphoma with Rituximab
28. Nucleotide sequences of Immunoglobulin μ heavy chain deletion mutants.
29. Complement activation by IgM: evidence for the importance of the third constant domain of the μ heavy chain.
30. Biochemical genetics of the mouse IgM system
31. Immunoglobulin molecular genetics: the prospects for mutational analysis of the chromosomal immunoglobulin genes
32. Sustained Immune Competency and Long Term Molecular Remissions in FL Patients with FLIPI Risk Factors >1, Treated Front Line with R-CHOP Followed by Consolidative 90Y-Radioimmunotherapy and Maintenance Rituximab
33. Nucleotide sequences of Immunoglobulin {micro} heavy chain deletion mutants
34. After Hours in the ED: Is It Time For Physician Call Compensation?
35. Management of newly diagnosed high-risk and intermediate-risk follicular lymphoma with 90 Y ibritumomab tiuxetan in a phase II study.
36. Lack of prognostic value of FCGR3A-V158F polymorphism in non-Hodgkin's lymphoma.
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.